For the development of combination products, pharma and biotech companies have the option to establish an assembly and packaging infrastructure internally or to outsource to a contract manufacturing organisation. One such organisation, SHL, explains what the benefits are of using a manufacturing partner and outlines what it can offer in terms of an integrated process.
In the modern world of injectable drugs, one of the major considerations for pharma is choosing partner companies for the development and manufacture of the injection device components. Adam Shain, discusses several of the considerations that go into ensuring that the best possible partner is selected.
The autoinjector market is booming and is predicted to continue doing so for some time to come. In order to capitalise on this, pharma companies are looking to use their autoinjectors for multiple medications. David Philbrick presents the case for bringing on metal component manufacturers in the initial design phase to make the most out of the crucial expertise they can offer.
A NEW VALUE PROPOSITION OF SMART DEVICES: ADVANCED MEDICATION ADHERENCE MONITORING IN CLINICAL TRIALS
Andreas Schneider explores a new value proposition of smart injection systems, introducing how advanced adherence monitoring services resolve some of the key challenges of clinical research practice regarding costs, adherence, data quality and integrity, Dr Schneider explains which technical features are needed for smart devices to provide value-adding adherence monitoring services, using SmartPilot for YpsoMate as a case study.
Using Noble’s recent partnership with BD to develop trainers for BD’s UltraSafe™ needle safety technology as an example, Joe Reynolds discusses the importance of training devices for the successful onboarding of patients beginning to use self-injected therapeutics, and how Noble’s training devices are designed to be faithful to the look and feel of the real product.